Company Filing History:
Years Active: 2006
Title: Michelle Haynes Pauling: Innovator in Monoclonal Antibody Research
Introduction
Michelle Haynes Pauling is a prominent inventor based in San Mateo, CA (US). She has made significant contributions to the field of biomedical research, particularly in the development of human monoclonal antibodies. With a total of 2 patents, her work focuses on innovative solutions for combating diseases such as HIV and cancer.
Latest Patents
Her latest patents include "Human monoclonal antibodies against human CXCR4" and "Human monoclonal antibody against coreceptors for human immunodeficiency virus." The first patent provides compositions that comprise antibodies against membrane proteins, specifically chemokine receptors. These monoclonal human antibodies against human CXCR4 are capable of inhibiting HIV infection and chemotaxis in human breast cancer cells. They can be utilized as prophylactics or therapeutics to prevent and treat HIV infection and cancer, as well as for screening drugs and diagnosing related diseases. The second patent focuses on antibodies against coreceptors for HIV, such as CCR5 and CXCR4. These antibodies bind to CCR5 with high affinity and can inhibit HIV infection at low concentrations, serving similar therapeutic and diagnostic purposes.
Career Highlights
Michelle is currently associated with Genetastix Corporation, where she continues her groundbreaking research. Her work has positioned her as a key figure in the fight against HIV and cancer, showcasing her dedication to improving health outcomes through innovative science.
Collaborations
She collaborates with notable colleagues, including Shaobing Benjamin Hua and Li Zhu, who contribute to her research endeavors.
Conclusion
Michelle Haynes Pauling's contributions to monoclonal antibody research exemplify her commitment to advancing medical science. Her innovative patents and collaborations highlight her role as a leading inventor in the field.